LTX-315’s ability to induce complete regression and systemic protective immune responses in the murine B16 melanoma model has been published in two cancer immunotherapy journals:

Camilio, et al., Cancer Immunol, Immunother. 2014, 63:601-13

Camilio, et al., OncoImmunology, 2014; 3: e29181

B16 melanoma is known as a tumor that is notoriously difficult to treat. In collaboration with University of Tromsø we have shown that LTX-315 is able to both cure and prevent metastasis in the B16 melanoma model.